Nicholas G. Mehler Partner

New YorkNew Jersey
T 973.597.2364 | F 973.597.2365



Nick concentrates his practice on licensing and commercial contracts for pharmaceutical, software, and other technology-based businesses. Clients–ranging from startup ventures to Fortune 100 companies–value his significant experience with development and licensing deals, strategic alliances, pharmaceutical product divestitures, IT procurement, manufacturing agreements, and distribution agreements.

Nick is particularly adept at analyzing complex intellectual property issues triggered by mergers and acquisitions, as well as by venture capital investments. He is also effective at crafting and implementing practical solutions related to privacy law matters.

Representative Engagements

Life Sciences
  • Represented G&W Laboratories, Inc. in a complex transaction with Teva Pharmaceuticals USA, Inc. for the acquisition/in-licensing of rights to a portfolio of pharmaceutical products, acquisition of a pharmaceutical manufacturing facility and related supply arrangements.
  • Represented Covis Pharma S.à.r.l in its acquisitions of pharmaceutical product portfolios from sanofi-aventis U.S. and GlaxoSmithKline LLC, and in its subsequent sale of assets to Concordia Pharmaceuticals Inc.
  • Represented Stryker Orthopaedics in negotiating an agreement with Osiris Therapeutics, Inc. for exclusive, worldwide marketing rights to BIO4™ viable bone matrix allografts.
  • Represented Celldex Therapeutics, Inc. in negotiating a clinical trial collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination use of Celldex and BMS cancer immunotherapies.
  • Represented Saladax Biomedical, Inc. in negotiating a strategic partnership agreement with Shanghai Fosun Long March Medical Science Co., Ltd. for the commercialization of Saladax’s proprietary diagnostic products in China.
Information Technology
  • Represented Flatiron Health, Inc. in negotiating a strategic alliance agreement with Varian Medical Systems, Inc. for the marketing of Flatiron Health’s electronic medical records software to Varian customers.
  • Represented Johnson & Johnson Services, Inc. in negotiating an agreement with NTT America, Inc. for the provision of NTT data center services to Johnson & Johnson companies worldwide.
  • Represented Knewton, Inc. in negotiating strategic alliance agreements with Pearson Education, Houghton Mifflin Harcourt, Sanoma Learning, Cambridge University Press, MacMillan and other educational publishers in the U.S., Europe and South America for the integration of Knewton’s adaptive learning technology into online learning courses.
  • Represented Cytec Industries Inc. in negotiating agreements with SAP America, Inc. and Deloitte Consulting LLP for the licensing and implementation of SAP software for Cytec’s businesses worldwide.
  • Represented Yext, Inc. in negotiating over 100 agreements with publishers, resellers and customers related to Yext’s online advertising services.
  • Represented Wyndham Worldwide Operations, Inc. in agreements with Microsoft to migrate all Wyndham corporate email users to Microsoft’s cloud-based email solution.

Press Mentions

Lowenstein Sandler represented Matawan Pharmaceuticals LLC in the sale of Retin-A® (tretinoin) to Perrigo Company plc (“Perrigo”) (NYSE: PRGO; TASE). Generic and brand sales of Retin-A®, a topical treatment for acne vulgaris, were valued at approximately $290 million for the 12-month period ending November 2015. The Lowenstein deal team was led by Michael Lerner and included Nick Mehler, Sam KhanNick Samedi and Robert Bee. , January 25, 2016
Lowenstein Sandler’s Tech Group represented Flatiron Health in a funding round led by the global pharmaceutical company Roche. According to the New York Times, the financing was $175M. Flatiron Health is a big data health tech startup that gathers and analyzes data on cancer treatments and produces software to enhance the quality of patient care. Flatiron’s OncologyCloud software platform connects patients, physicians, life sciences companies, and researchers. As part of this deal, Roche will also purchase several of Flatiron’s subscription-based software products. The Lowenstein team included Ed Zimmerman, Peter Ehrenberg, Eric Weiner, Nicholas Mehler, Darren Bilotto, Jocqui Kaup, Matt Holbreich, and Jeff Silberman. , January 11, 2016
Lowenstein Sandler is representing long-time client, Indorama Ventures Public Company Limited, in the proposed acquisition of a Decatur, Alabama manufacturing facility from BP Amoco Chemical Company. The definitive purchase agreement for the 1,000-acre, 450-employee facility was signed on January 6, 2016. The acquisition of the Decatur facility is the sixth investment in North America in which Lowenstein represented Indorama and the second in the past year. In 2007, Lowenstein represented Indorama in acquiring the land rights and raw material supply agreement from BP to build its AlphaPet plant, which is co-located at the Decatur site. The Lowenstein team was led by partner Nicholas San Filippo IV, and included Nicholas Mehler, Christine Osvald-Mruz, Brian Silikovitz, Norman Spindel, Stuart Yusem, Samiul Khan, Ethan Skerry, Lesley Pruzansky Adamo, Eugene Cheval, Robert Bee, and Meredith Jewitt. , January 6, 2016
View More...

Related Areas

Corporate
Franchise and Distribution
Life Sciences
Outsourcing
Privacy and Information Security
The Tech Group
Trademark Prosecution and Enforcement

Education


New York University School of Law ( J.D. , 1998 ) , cum laude
Yale University ( B.A. , 1994 ) , magna cum laude

Bar Admissions


New York
New Jersey